节点文献
国产重组链激酶与进口重组组织型纤溶酶原激活剂静脉溶栓治疗急性心肌梗塞的临床对比观察
THECLINICALCOMPARISIONOFINTRAVENOUS THROMBOLYTIC THERAPYWITHDOMESTIC RECOMBINANTSTREPTOKINASE ANDFOREIGN RECOMBINANTTISSUETYPE PLASMINOGEN ACTIVATORINPATIENTS WITHACUTE MYOCARDIALINFARCTION
【摘要】 目的:比较重组链激酶(r-sk)与重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓对急性心肌梗塞的效果与其副作用;方法:急性心肌梗塞患者发病6h内者26例给予静脉rt-PA,另27例给予静脉内r-sk溶栓;结果:rt-PA组、r-sk组临床血管再通率分别为84.6%与77.3%(P>0.05),前者局部出血并发症为11.5%,呼吸道出血为7.7%,后者分别为3.7%与0(P>0.05);结论:静脉r-sk溶栓血管再通率及出血并发症与rt-PA无明显差异。
【Abstract】 Objective:T5,5BZTocomparetheeffectivenessandcomplicationsofintravenousrecombinantstreptokinase(rsk)andrecombinanttissuetypeplasminogenactivator(rtPA)inpatientswithacutemyocardialinfarction(AMI). Methods: 26patientsinrtPAgroupand27patientsinrskgroupwereincludedinthestudy,andeitherofthemweresimultaneouslytreatedwithintravenousrskrtPA. Results: TheclinicalreperfusionratesinrtPAandrskgroupwere84.6%and77.3%(P>0.05),respectively.WhileinrtPAgroupthepartialbleedingcomplicationratewas11.5%.respiratorybleedingratewas7.7%.Inrskgroupwere3.7%and0(P>0.05),respectively. Conclusion:5BZThepatientswithAMItreatedwithintravenousrskrtPAwithin6hoursafteronsetofsymptomshadntobviousdifferenceofreperfusionratesandhemorrhagiccomplications.
- 【文献出处】 河北医学 ,HEBEI MEDICINE , 编辑部邮箱 ,1999年07期
- 【分类号】R542.220.5
- 【被引频次】2
- 【下载频次】18